|  | Faller, Bernard / Urban, Laszlo (Hrsg.) Hit and Lead Profiling Identification and Optimization of Drug-like Molecules Methods and Principles in Medicinal Chemistry (Band 43) Herausgegeben von Mannhold, Raimund / Kubinyi, Hugo / Folkers, Gerd
  1. Auflage - August 2009 179,- Euro 2009. XXX, 503 Seiten, Hardcover 82 Abb. (16 Farbabb.), 35 Tab. - Handbuch/Nachschlagewerk - ISBN-10: 3-527-32331-7 ISBN-13: 978-3-527-32331-9 - Wiley-VCH, Weinheim
Preis inkl. Mehrwertsteuer zzgl. Versandkosten.

Inhalt
Probekapitel
Index
Langtext Dieses praxisnahe Handbuch spricht Aspekte sowohl der Wirksamkeit als auch der Sicherheit von Wirkstoffen an und erleichtert Ihnen damit die Entscheidung im Zuge einer Risiko/Nutzen-Bewertung im frühen Stadium des Entwicklungsprozesses. Herangezogen werden sowohl in-vitro-Verfahren als auch geeignete Computerprogramme.
Aus dem Inhalt PART 1: Introduction: The one Airplane that Flies - Selection of the Right one Molecule for Clinical use. 1 Process logistics, testing strategies and automation aspects 2 Prediction of drug-likeness and its integration 3 Integrative risk assessment PART 2: ADME Profiling: What is Drug Likeness? 4 Solubility and Aggregation 5 In silico tools and in vitro HTS approaches to determine lipophilicity during the drug discovery process 6 Membrane permeability - measurement and prediction in drug discovery 7 Drug Metabolism and Reactive Metabolites 8 Drug-Drug Interactions: Screening for liability and assessment of risk 9 Plasma Protein Binding and Volume of Distribution: Determination, Prediction and Use in Early Drug Discovery 10 Putting it all together PART 3: Safety Profiling: What is Considered Safe in the Clinic? 11 Genetic Toxicity: in vitro Approaches for Hit and Lead Profiling 12 In vitro Safety Pharmacology Profiling: An important tool to decrease attrition 13 Knowledge-based and Computational Approaches to in vitro Safety Pharmacology PART 4: Organ Specific Toxicity 14 Discovery Toxicology Screening: Predictive, In Vitro Cytotoxicity 15 Predicting Drug-Induced Hepatotoxicity: In Vitro, In Silico, and In Vivo Approaches 16 Should cardiosafety be ruled by hERG inhibition? Early testing scenarios and integrated risk assessment 17 Haematotoxicity: in vitro and ex vivo compound profiling 18 Profiling Adverse Immune Effects 19 In Vitro Phototoxicity Testing: A Procedure Involving Multiple Endpoints
|
|
| |